Leronlimab (PRO 140): A Monoclonal CCR5 Antagonist in HIV Research
1. Introduction: A Monoclonal Antibody Against CCR5 Leronlimab, also known by its development name PRO 140, is a humanized IgG4…
Maraviroc: The CCR5 Antagonist and the Entry-Inhibitor Class in HIV Therapy
1. Introduction: An Entry Inhibitor That Targets the Host Maraviroc (marketed as Selzentry in the United States and Celsentri in…
Post-Exposure Prophylaxis (PEP) for HIV: Timing, Regimens, and Evidence
1. Introduction: Definition and Rationale Post-exposure prophylaxis (PEP) for HIV is the short-term use of antiretroviral drugs to prevent infection…
Lenacapavir: A First-in-Class Capsid Inhibitor for Six-Monthly HIV Prevention and Treatment
1. Introduction: A New Class of Antiretroviral For four decades, the pharmacological treatment and prevention of HIV-1 has been dominated…
Combination Antiretroviral Therapy: How HIV Became a Manageable Chronic Infection
1. Introduction: From Fatal Syndrome to Chronic Disease When the acquired immunodeficiency syndrome (AIDS) was first characterized in the early…